tirzepatide versus semaglutide for weight loss vs Tirzepatide vs Semaglutide: A Doctor's

These statements have not been evaluated by the Food and Drug Administration.

Weight Outcomes After 1 year of follow-up with continuous treatment, the mean (SD) weight was 89.9 (22.4) kg in the semaglutide 2.4 mg cohort and 87.6 (22.6) kg in the tirzepatide cohort (Table 3)

These Phase 3 trials enrolled thousands of participants across multiple studies, providing robust evidence for efficacy and safety

A 300 mcg dose would be 12 units

Clinical Rationale: Patient-specific justifications highlighting Wegovys unique benefits, such as superior weight reduction and lower adverse effect profiles compared to alternative medications